Provided by Tiger Fintech (Singapore) Pte. Ltd.

Karyopharm Therapeutics

6.16
-0.3500-5.38%
Volume:18.55K
Turnover:117.35K
Market Cap:51.84M
PE:-0.44
High:6.49
Open:6.49
Low:6.16
Close:6.51
Loading ...

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire
·
02 Nov 2024

Karyopharm Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
01 Nov 2024

Karyopharm Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
01 Nov 2024

Barclays Keeps Their Buy Rating on Karyopharm Therapeutics (KPTI)

TIPRANKS
·
01 Nov 2024

Karyopharm gains after changes to late-stage trial

seekingalpha
·
01 Nov 2024

Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Zacks
·
31 Oct 2024

Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024

PR Newswire
·
31 Oct 2024

BRIEF-Karyopharm Announces Favorable Change In Co-Primary Endpoint For Pivotal Phase 3 SENTRY Trial In Myelofibrosis

Reuters
·
31 Oct 2024

Karyopharm Therapeutics Inc - Co-Primary Endpoint Changed to Absolute Total Symptom Score (Abs-Tss)

THOMSON REUTERS
·
31 Oct 2024

Karyopharm Therapeutics Inc - Sentry Trial SAMPLE Size Increased to Approximately 350 Patients

THOMSON REUTERS
·
31 Oct 2024

Karyopharm Therapeutics Inc - Spleen Volume Response Rate ≥ 35% (Svr35) Remains Co-Primary Endpoint

THOMSON REUTERS
·
31 Oct 2024

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 Sentry Trial in Myelofibrosis

THOMSON REUTERS
·
31 Oct 2024

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

PR Newswire
·
31 Oct 2024

Karyopharm to Host Investor Event With Leading Myelofibrosis Kols and Provide a Favorable Study Design Update on October 31, 2024

THOMSON REUTERS
·
31 Oct 2024

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024

PR Newswire
·
31 Oct 2024

Karyopharm Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
29 Oct 2024